The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity

Nutrition and Diabetes

Volumn 3, Issue MAY, 2013, Pages

  Wargent, E T ^a   Zaibi, M S ^a   Silvestri, C ^b   Hislop, D C ^a   Stocker, C J ^a   Stott, C G ^c   Guy, G W ^c   Duncan, M ^c   Di Marzo, V ^b   Cawthorne, M A ^a  

^a UNIVERSITY OF BUCKINGHAM   (United Kingdom)

^b CNR   (Italy)

^c Porton Down Science Park   (United Kingdom)

Author keywords

Cannabinoid; DIO mice; Energy balance; Insulin sensitivity; Ob ob mice

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR AGONIST; CHOLESTEROL; DELTA 9 TETRAHYDROCANNABIVARIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; PALMITIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; ENERGY EXPENDITURE; FEMALE; FLUID INTAKE; FOOD INTAKE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIVER CELL; MOUSE; MYOTUBE; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PILOT STUDY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 84880536518     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2013.9     Document Type: Article

References (30)

1. Buggy Y, Cornelius V, Wilton L, Shakir SA. Risk of depressive episodes with rimonabant: a before and after modified prescription event monitoring study conducted in England. Drug Saf 2011; 34: 501-509.
2. Silvestri C, Di Marzo V. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. Expert Opin Investig Drugs 2012; 21: 1309-1322.
3. Parker LA, Rock EM, Limebeer CL. Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol 2011; 163: 1411-1422.
4. Janero DR, Lindsley L, Vemuri VK, Makriyannis A. Cannabinoid 1 G proteincoupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk. Expert Opin Drug Discov 2011; 6: 995-1025.
5. Silvestri C, Ligresti A, Di Marzo V. Peripheral effects of the endocannabinoid system in energy homeostasis: adipose tissue, liver and skeletal muscle. Rev Endocr Metab Disord 2011; 12: 153-162.
6. Bermudez-Silva FJ, Sanchez-Vera I, Sua'rez J, Serrano A, Fuentes E, Juan-Pico P et al. Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol 2007; 565: 207-211. (Pubitemid 46782769)
7. Deveaux V, Cadoudal T, Ichigotani Y, Teixeira-Clerc F, Louvet A, Manin S et al. Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS ONE 2009; 4: e5844.
8. Agudo J, Martin M, Roca C, Molas M, Bura AS, Zimmer A et al. Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age. Diabetologia 2010; 53: 2629-2640.
9. Romero-Zerbo SY, Garcia-Gutierrez MS, Sua'rez J, Rivera P, Ruz-Maldonado I, Vida M et al. Overexpression of cannabinoid CB2 receptor in the brain induces hyperglycaemia and a lean phenotype in adult mice. J Neuroendocrinol 2012; 24: 1106-1119.
10. Pertwee RG, Thomas A, Stevenson LA, Ross RA, Varvel SA, Lichtman AH et al. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo. Br J Pharmacol 2007; 150: 586-594. (Pubitemid 46355554)
11. Bá tkai S, Mukhopadhyay P, Horváth B, Rajesh M, Gao RY, Mahadevan A et al. D8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors. Br J Pharmacol 2012; 165: 2450-2461.
12. Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA et al. Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 2005; 146: 917-926. (Pubitemid 41722163)
13. Bolognini D, Costa B, Maione S, Comelli F, Marini P, Di Marzo V et al. The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol 2010; 160: 677-687.
14. Riedel G, Fadda P, McKillop-Smith S, Pertwee RG, Platt B, Robinson L. Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol 2009; 156: 1154-1166.
15. Wargent ET, O'Dowd J, Zaibi M, Gao D, Bing C, Trayhurn P et al. Contrasts between the effects of zinc a2-glycoprotein, a putative b3/2-adrenoceptor agonist, and the b3/2-adrenoceptor agonist BRL 35135 in C57Bl/6 (ob/ob) mice. J Endocrinol 2012; 216: 157-168.
16. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 2008; 51: 1356-1367.
17. Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkai S, Járai Z et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-825. (Pubitemid 32303781)
18. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284: R345-R353. (Pubitemid 36120150)
19. Poirier B, Bidouard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 2005; 7: 65-72.
20. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S. RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397. (Pubitemid 40523733)
21. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong W et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008; 118: 3160-3169.
22. Liu J, Zhou L, Xiong K, Godlewski G, Mukhopadhyay B, Tam J et al. Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology 2012; 142: 1218-1228.
23. Herling AW, Kilp S, Elvert R, Haschke G, Kramer W. Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Endocrinology 2008; 149: 2557-2566. (Pubitemid 351574492)
24. Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, Fleming S et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), D9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl) 2012; 219: 859-873.
25. Tedesco L, Valerio A, Cervino C, Cardile A, Pagano C, Vettor R et al. Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes 2008; 57: 2028-2036.
26. Cota D, Sandoval DA, Olivieri M, Prodi E, D'Alessio DA, Woods SC et al. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism. Obesity (Silver Spring) 2009; 17: 1641-1645.
27. De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011; 163: 1479-1494.
28. Kang JH, Goto T, Han IS, Kawada T, Kim YM, Yu R. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet. Obesity (Silver Spring) 2010; 18: 780-787.
29. Weiss L, Zeira M, Reich S, Har-Noy M, Mechoulam R, Slavin S et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 2006; 39: 143-151. (Pubitemid 43675258)
30. Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R et al. Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology 2008; 54: 244-249. (Pubitemid 350299408)